title: Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease.
abstract: BACKGROUND
  Immune response to oxidized low-density lipoprotein (oxLDL) may modulate the process of atherogenesis and cardiovascular disease.
  
  
  METHODS
  We performed a prospective, observational cohort study in 249 patients with end-stage renal disease (ESRD) to examine whether the serum titer of anti-oxLDL antibody can predict cardiovascular mortality.
  
  
  RESULTS
  The median anti-oxLDL antibody titer was 320 mU/mL at baseline. During the follow-up (63 +/- 23 months), 72 deaths including 34 cardiovascular deaths occurred. When the subjects were divided into two groups by the median titer, the high titer group showed a lower risk for cardiovascular mortality (P = 0.040 by Kaplan-Meier analysis and log-rank test). Multivariate Cox proportional hazards model indicated that the lower risk of cardiovascular death in the high titer group remained significant (hazard ratio of 0.46, 95%CI 0.23-0.95, P = 0.037) and independent of age, presence of vascular complications, presence of diabetes mellitus, and elevated C-reactive protein. In contrast, anti-oxLDL antibody titer was not associated with non-cardiovascular mortality.
  
  
  CONCLUSIONS
  These results demonstrate, to our knowledge for the first time, that serum anti-oxLDL antibody titer is an independent predictor of cardiovascular mortality in a cohort of patients with ESRD.
authors.affiliation: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan. t.shoji@med.osaka-cu.ac.jp
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Shoji
authors.forename: Mariko
authors.initials: M
authors.lastname: Fukumoto
authors.forename: Eiji
authors.initials: E
authors.lastname: Kimoto
authors.forename: Kayo
authors.initials: K
authors.lastname: Shinohara
authors.forename: Masanori
authors.initials: M
authors.lastname: Emoto
authors.forename: Hideki
authors.initials: H
authors.lastname: Tahara
authors.forename: Hidenori
authors.initials: H
authors.lastname: Koyama
authors.forename: Eiji
authors.initials: E
authors.lastname: Ishimura
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Nakatani
authors.forename: Takami
authors.initials: T
authors.lastname: Miki
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Tsujimoto
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Tabata
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Nishizawa
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000276:immunology* / Q000401:mortality; D006973:Hypertension / Q000276:immunology* / Q000401:mortality; D007676:Kidney Failure, Chronic / Q000276:immunology* / Q000401:mortality; D008077:Lipoproteins, LDL / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D001323:Autoantibodies; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein